case_images: PMC11440991_01
case_images: Staging [68Ga]Ga-DOTA-NOC PET/CT demonstrated multiple [68Ga]Ga-DOTA-NOC avid liver and intra-abdominal lymph node metastases.
case_images: fnume-03-1193880-g001.jpg
case_images: PMC11440991_01_fnume-03-1193880-g001.jpg
case_images: F1
case_images: A staging [68Ga]Ga-DOTA-NOC PET/CT demonstrated multiple [68Ga]Ga-DOTA-NOC avid liver and intra-abdominal lymph node metastases (Figure 1).
case_images: (A) Demonstrating post-therapy uptake in whole-body imaging and (B) post-therapy tumor markers for patient A.
case_images: fnume-03-1193880-g002.jpg
case_images: PMC11440991_01_fnume-03-1193880-g002.jpg
case_images: F2
case_images: The overall survival since the start of therapy is 37 months (Figure 2A demonstrating post-therapy uptake in whole body imaging after each cycle). The uptake in whole-body imaging and Figure 2B show post-therapy tumor markers.
case_images: PMC11440991_02
case_images: Staging [68Ga]Ga-DOTATATE PET/CT demonstrated multiple [68Ga]Ga-DOTA-TATE avid liver lesions with no other sites of abnormal uptake.
case_images: fnume-03-1193880-g003.jpg
case_images: PMC11440991_02_fnume-03-1193880-g003.jpg
case_images: F3
case_images: A staging [68Ga]Ga-DOTATATE PET/CT demonstrated multiple [68Ga]Ga-DOTA-TATE avid liver lesions with no other sites of abnormal uptake (Figure 3).
case_images: (A) Demonstrating post-therapy uptake in whole-body images and (B) post-therapy tumor markers for patient B.
case_images: fnume-03-1193880-g004.jpg
case_images: PMC11440991_02_fnume-03-1193880-g004.jpg
case_images: F4
case_images: The treatment resulted in a biochemical response (Figure 4A shows the post-therapy uptake in whole-body images and Figure 4B shows the post-therapy tumor markers).